ClinicalTrials.gg
Enrolling by invitationNCT07064525Updated Jul 14, 2025

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

A Phase 2 interventional study of SPC1001 Low and SPC5002 in Hypertension (HTN), NYHA Class III Heart Failure and NYHA Class IV Heart Failure, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 7 months after the study started (first participant enrolled Dec 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 353 studies in Hypertension with a site in Korea, Republic of — 31 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Planned enrollment
70th of 304
252 · median 110
Started
2024
with 14 others
Phase 2
21 of 353
1 open now
Primary completion
2025-12
later than 14 of 40 live
Registered
330th of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 70th largest by planned enrollment of the 304 interventional ones that give a count, is one of 15 that started in 2024, is one of 21 in phase 2, reaches primary completion later than 14 of the 40 other live ones, and was the 330th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

31 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.

- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.

- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.

- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.

Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.

03

Conditions studied

  • Hypertension (HTN)
  • NYHA Class III Heart Failure
  • NYHA Class IV Heart Failure
  • Diabete Mellitus

Keywords

  • blood pressure
  • phase 2b
  • low dose combination therapy
  • candesartan
  • amlodipine
  • indapamide
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (estimated)

Study arms

  • Active comparator
    SPC1001 Low

    low-dose combination therapy

    Drug: SPC1001 Low

  • Active comparator
    SPC5002

    low-dose combination therapy

    Drug: SPC1001 Low · Drug: SPC5002

  • Active comparator
    SPC5003

    low-dose combination therapy

    Drug: SPC1001 Low · Drug: SPC5003

  • Active comparator
    SPC5004

    low-dose combination therapy

    Drug: SPC1001 Low · Drug: SPC5004

Interventions

  • DrugSPC1001 Low

    low-dose combination therapy

  • DrugSPC5002

    low-dose combination therapy

  • DrugSPC5003

    low-dose combination therapy

  • DrugSPC5004

    low-dose combination therapy

06

What researchers measure

Primary outcomes

  1. The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8

    Time frame: change in MSSBP from baseline at week 8

07

Study locations

1 site
  • CHA Gangnam Medical Center, CHA University
    Seoul, 06135, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — It is planned to be publicly available in the form of a future journal submission

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 12 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 14, 2025
StartActual
Dec 5, 2024
Primary completionEst.
Dec 15, 2025
CompletionEst.
Feb 28, 2026
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07064525
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Dec 5, 2024
Primary completion
Dec 15, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jul 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion